Gerold Meinhardt
Vice President, Head Global Team Leads, Early Oncology Daiichi Sankyo
Gerold Meinhardt, MD, PhD joined Daiichi Sankyo in June 2020. As of July 14, 2025, he is Vice President; Head Early Oncology Team Leads.
Prior to that, he was Vice President, Global Team Lead, responsible for the development of trastuzumab deruxtecan (DS-8201, ENHERTU), the company’s lead ADC (co-developed with AstraZeneca), approved for different indications in multiple countries worldwide.
Seminars
Thursday 11th June 2026
Exploring the Success of Dxd ADC Platform in Optimizing Clinical Efficacy Through Plasma-Stable Linker-Payload Technology & Optimized DAR
4:00 pm
- Analyzing the design innovations of the DXd ADC platform, specifically the plasma-stable linker-payload to understand its role in enhancing tumor selectivity
- Discussing translational and clinical outcomes of this platform in achieving efficacy in multiple tumor types
- Demonstrating bystander antitumor effect and its enhanced ability in tumor killing
Tuesday 9th June 2026
Analyzing Current Trends With Antibody Formats, Payloads, Linkers & Conjugation Technologies to Explore Future Areas of Innovation
9:30 am
- Evaluating innovations in antibody formats and novel conjugates to bolster the success of tumor targeting
- Examining advances in payloads and linkers to improve potency and stability
- Investigating emerging conjugation technologies for efficient manufacturing of ADCs
